18F-FDG PET/CT在复发性生殖细胞肿瘤中的诊断与预后价值
这项双中心回顾性研究纳入114例疑似复发性睾丸生殖细胞肿瘤患者,评估18F-FDG PET/CT的诊断性能、预后价值及对治疗决策的影响。PET/CT的灵敏度86.8%、特异度90.2%、准确率88.4%,并在23%(26/114)的病例中显著影响治疗管理;阴性扫描患者的无进展生存期和总生存期均显著长于阳性扫描患者。
要点
- 18F-FDG PET/CT诊断复发性睾丸生殖细胞肿瘤的灵敏度86.8%、特异度90.2%、准确率88.4%。
- PET/CT阳性与疾病进展风险升高相关(HR=24.3,95%CI 14.1-40.6;p=0.03)。
- PET/CT在26/114(23%)病例中显著影响治疗决策。
核心结论
- 18F-FDG PET/CT在疑似复发性睾丸生殖细胞肿瘤患者中具有很好的诊断性能,并在评估无进展生存率和总生存率方面具有重要预后价值。
- 18F-FDG PET/CT影响了23%患者的治疗方案,因此在再分期过程中具有显著影响。
研究设计与样本
- 这项双中心回顾性研究从两个中心共31,500例18F-FDG PET/CT肿瘤学检查数据库中评估了114例睾丸生殖细胞肿瘤患者。
- 全部114例患者均因疑似复发疾病接受18F-FDG PET/CT检查。
- 以组织学(17例)、其他诊断影像学方法(对比增强CT 89例和MRI 15例)及临床随访(114例)作为参考标准。
- 采用Kaplan-Meier生存分析计算无进展生存期和总生存率,采用单因素Cox回归分析确定进展率(风险比)。
主要发现
- 52例18F-FDG PET/CT病理阳性表现的患者中47例 confirmed 复发性生殖细胞肿瘤,其中18例经组织学证实、29例经其他诊断影像学方法/随访证实。
- 18F-FDG PET/CT的灵敏度86.8%、特异度90.2%、准确率88.4%、阳性似然比8.85、阴性似然比0.14、检验前比值比0.85、检验后比值比8.85。
- 18F-FDG PET/CT在26/114(23%)病例中显著影响治疗管理:12例从姑息治疗转为治愈性治疗,6例从「观察等待」转为新化疗方案,8例检查无异常发现者采取「观察等待」策略。
- 2年和5年随访时,18F-FDG PET/CT阴性患者的无进展生存率显著长于病理阳性患者(98%和95% vs 48%和38%;p=0.02)。
- 检查无异常发现也与更长的总生存期相关(2年后98%、5年后95%;p=0.02)。
关键数值与推荐
- 以诊断时晚期疾病和升高的β-人绒毛膜促性腺激素或甲胎蛋白进行检验时,其预后价值亦得到证实(III期-PET+的HR=7.3,p=0.03;HCGB升高-PET+的HR=14.3,p=0.02;AFP升高-PET+的HR=10.7,p=0.01)。
- 多因素分析中,仅18F-FDG PET/CT病理阳性和TNM分期方面的晚期疾病是疾病进展和总生存的预测因素。
- 18F-FDG PET/CT在预测无进展生存(卡方从24增至40,p<0.001)和总生存(卡方从32增至38,p=0.003)方面均显示出相对于其他变量的增量价值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of this bicentric retrospective study was to assess the diagnostic performance, the prognostic value, the incremental prognostic value and the impact on therapeutic management of 18F-FDG PET/CT in patients with suspected recurrent germinal cell testicular carcinoma (GCT). MATERIALS AND METHODS: From the databases of two centers including 31,500 18F-FDG PET/CT oncological studies, 114 patients affected by GCT were evaluated in a retrospective study. All 114 patients underwent 18F-FDG PET/CT for suspected recurrent disease. Diagnostic performance of visually interpreted 18F-FDG PET/CT and potential impact on the treatment decision were assessed using histology (17 patients), other diagnostic imaging modalities (i.e., contrast enhanced CT in 89 patients and MRI in 15) and clinical follow-up (114 patients) as reference. Progression-free survival (PFS) and overall survival (OS) rates were computed by means of Kaplan-Meier survival analysis. The progression rate (Hazard Ratio-HR) was determined using univariate Cox regression analysis by considering various clinical variables. RESULTS: Recurrent GCT was confirmed in 47 of 52 patients with pathological 18F-FDG PET/CT findings, by means of histology in 18 patients and by other diagnostic imaging modalities/follow-up in 29. Sensitivity, specificity, accuracy, positive and negative likelihood ratio (LR+ and LR-, respectively), pre-test Odds-ratio and post-test Odds-ratio of 18FDG PET/CT were 86.8%, 90.2%, 88.4%, 8.85, 0.14, 0.85, 8.85, respectively.18F-FDG PET/CT impacted significantly on therapeutic management in 26/114 (23%) cases (from palliative to curative in 12 patients, from "wait and watch" to new chemotherapy in six patients and the "wait-and-watch" approach in eight patients with unremarkable findings). At 2 and 5-year follow-up, PFS was significantly longer in patients with a negative than a pathological 18F-FDG PET/CT scan (98% and 95% vs 48% and 38%, respectively; p = 0.02). An unremarkable scan was associated also with a longer OS (98% after 2 years and 95% after 5 years, p = 0.02). At univariate Cox regression analysis, a pathological 18F-FDG PET/CT scan was associated with an increased risk of disease progression (HR = 24.3, CI 95% 14.1-40.6; p = 0.03) and lower OS (HR = 17.3 CI 95% 4,9-77; p < 0.001). Its prognostic value was confirmed also if tested against advanced disease at diagnosis and rising Human Chorionic Gonadotropin Beta (HCGB) or Alpha-Fetoprotein (AFP) (HR = 7.3 for STAGE III-PET+, p = 0.03; HR = 14.3 elevated HCGB-PET+, p = 0.02; HR 10.7 elevated AFP-PET+, p = 0.01) At multivariate analysis, only a pathological 18F-FDG PET/CT scan and advanced disease in terms of TNM staging were predictors of disease progression and OS. 18F-FDG PET/CT showed incremental value over other variables both in predicting PFS (chi-square from 24 to 40, p < 0.001) and OS (chi-square from 32 to 38, p = 0.003). CONCLUSION: 18F-FDG PET/CT has a very good diagnostic performance in patients with suspected recurrent GCT and has an important prognostic value in assessing the rate of PFS and OS. Furthermore, 18F-FDG PET/CT impacted the therapeutic regimen in 23% of patients, thus providing a significant impact in the restaging process.
引用
- Alongi P, Evangelista L, Caobelli F, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. Eur J Nucl Med Mol Imaging. 2017. PMID: 28828589. doi:10.1007/s00259-017-3811-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。